Companies
Incyte
BiotechnologyWilmington, DelawareINCY2,844 employees
More about Incyte
Biopharmaceutical company that develops and sells medicines for blood cancers, other cancers and inflammatory skin conditions
Revenue
$5.14B
Fiscal 2025, up 21%
Employees
2,844
As of December 2025
Stock
INCY
Nasdaq
Headquarters
Wilmington, Delaware
CEO
Bill Meury
Since June 2025
BrandsJakafi, Opzelura
Current strategyGrowing Jakafi and Opzelura while moving pipeline assets into late-stage development, with 14 pivotal trials expected to be underway by the end of 2026
CompetitorsExelixis, BeiGene, Biogen
Related companiesNovartisVertex PharmaceuticalsRegeneron Pharmaceuticals
Checked October 11, 2026 · Sources: businesswire.com, sec.gov, businesswire.com (2)
Be the first to post about Incyte
No one has started a discussion here yet. Yours is anonymous and appears right away, and we don’t store who wrote it.
Or follow Incyte to see the first post in your watchlist.
Follow Incyte in a feed reader, no account needed: RSS feed